Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked higher than
92% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. KPTI: No Debt )
KPTI' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Equity to Asset 0.97
KPTI's Equity to Asset is ranked higher than
99% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. KPTI: 0.97 )
KPTI' s 10-Year Equity to Asset Range
Min: -21.26   Max: 0.98
Current: 0.97

-21.26
0.98
Interest Coverage No Debt
KPTI's Interest Coverage is ranked higher than
80% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.95 vs. KPTI: No Debt )
KPTI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

Z-Score: 112.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -26517.95
KPTI's Operating margin (%) is ranked lower than
56% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.59 vs. KPTI: -26517.95 )
KPTI' s 10-Year Operating margin (%) Range
Min: -8772.61   Max: -2506.31
Current: -26517.95

-8772.61
-2506.31
Net-margin (%) -26493.59
KPTI's Net-margin (%) is ranked lower than
56% of the 857 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.31 vs. KPTI: -26493.59 )
KPTI' s 10-Year Net-margin (%) Range
Min: -8771.83   Max: -2505.99
Current: -26493.59

-8771.83
-2505.99
ROE (%) -50.75
KPTI's ROE (%) is ranked higher than
51% of the 874 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. KPTI: -50.75 )
KPTI' s 10-Year ROE (%) Range
Min: -53.44   Max: -53.44
Current: -50.75

ROA (%) -42.10
KPTI's ROA (%) is ranked higher than
51% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.02 vs. KPTI: -42.10 )
KPTI' s 10-Year ROA (%) Range
Min: -372.3   Max: -42.56
Current: -42.1

-372.3
-42.56
ROC (Joel Greenblatt) (%) -7483.36
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 904 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.17 vs. KPTI: -7483.36 )
KPTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -11975.31   Max: -9718.65
Current: -7483.36

-11975.31
-9718.65
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

KPTI Guru Trades in Q4 2013

Steven Cohen 9,624 sh (New)
» More
Q1 2014

KPTI Guru Trades in Q1 2014

Steven Cohen Sold Out
» More
Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

KPTI Guru Trades in Q3 2014

Steven Cohen 39,400 sh (+392.5%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Karyopharm Therapeutics Inc.

Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Inc. and Nimble Storage Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Karopharm Therapeuticcs Inc, Methode Electronics Inc, Gilead Sciences Inc, and Nimble Storage Inc. Read more...

Ratios

vs
industry
vs
history
P/B 6.08
KPTI's P/B is ranked higher than
60% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. KPTI: 6.08 )
KPTI' s 10-Year P/B Range
Min: 5.2   Max: 9.74
Current: 6.08

5.2
9.74
P/S 4879.58
KPTI's P/S is ranked lower than
57% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.96 vs. KPTI: 4879.58 )
KPTI' s 10-Year P/S Range
Min: 359.57   Max: 673.14
Current: 4879.58

359.57
673.14
EV-to-EBIT -18.68
KPTI's EV-to-EBIT is ranked higher than
57% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. KPTI: -18.68 )
KPTI' s 10-Year EV-to-EBIT Range
Min: -29.7   Max: -14.3
Current: -18.68

-29.7
-14.3
Current Ratio 37.11
KPTI's Current Ratio is ranked higher than
99% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. KPTI: 37.11 )
KPTI' s 10-Year Current Ratio Range
Min: 0.49   Max: 47.98
Current: 37.11

0.49
47.98
Quick Ratio 37.11
KPTI's Quick Ratio is ranked higher than
99% of the 890 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. KPTI: 37.11 )
KPTI' s 10-Year Quick Ratio Range
Min: 0.49   Max: 47.98
Current: 37.11

0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.30
KPTI's Price/Net Cash is ranked higher than
94% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. KPTI: 6.30 )
KPTI' s 10-Year Price/Net Cash Range
Min: 4.47   Max: 10.72
Current: 6.3

4.47
10.72
Price/Net Current Asset Value 6.30
KPTI's Price/Net Current Asset Value is ranked higher than
91% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. KPTI: 6.30 )
KPTI' s 10-Year Price/Net Current Asset Value Range
Min: 4.47   Max: 10.72
Current: 6.3

4.47
10.72
Price/Tangible Book 6.09
KPTI's Price/Tangible Book is ranked higher than
68% of the 945 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. KPTI: 6.09 )
KPTI' s 10-Year Price/Tangible Book Range
Min: 4.4   Max: 10.28
Current: 6.09

4.4
10.28
Earnings Yield (Greenblatt) -5.40
KPTI's Earnings Yield (Greenblatt) is ranked higher than
55% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. KPTI: -5.40 )
KPTI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -5.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:25K.Germany
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Other Websites
8:05 am Karyopharm Therapeutics presents data on oncology pipeline at EORTC-NCI-AACR annual meeting Nov 24 2014
Karyopharm Presents Data on Oncology Pipeline at EORTC-NCI-AACR Annual Meeting Nov 24 2014
KARYOPHARM THERAPEUTICS INC. Financials Nov 19 2014
Karyopharm Therapeutics upgraded by Oppenheimer Nov 10 2014
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
Karyopharm Initiates Registration-Directed Clinical Study Of Selinexor (KPT-330) In Patients With... Nov 10 2014
Q3 2014 Karyopharm Therapeutics Inc Earnings Release - Before Market Open Nov 10 2014
Karyopharm Reports Third Quarter 2014 Financial Results and Highlights Recent Progress Nov 10 2014
Karyopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With... Nov 10 2014
The ASH 2014 Abstract Stampede Just Happened Nov 06 2014
Karyopharm Announces Data Presentations at American Society of Hematology Annual Meeting Nov 06 2014
Karyopharm to Present at Credit Suisse 2014 Healthcare Conference Nov 05 2014
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 04 2014
Karyopharm Appoints J. Scott Garland to Its Board of Directors Nov 04 2014
Karyopharm to Report Third Quarter 2014 Financial Results on November 10, 2014 Oct 30 2014
Karyopharm Expands Global Presence With European Subsidiary Oct 27 2014
Karyopharm Expands Global Presence With European Subsidiary Oct 27 2014
Why Karyopharm Therapeutics (KPTI) Stock Might be a Great Pick Oct 24 2014
Merrill Lynch’s 5 Destroyed Biotech Stocks With 100% or More Upside Potential Oct 20 2014
UPDATE: Webush Initiates Coverage On Karyopharm Therapeutics Inc On Selinexor Potential Oct 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK